Recent Filing Shows That Rep. Josh Gottheimer Sold Over $32K Worth of Abbott Laboratories Stock

A April filing shows that Representative Josh Gottheimer reported a sale in Abbott Laboratories ABT, valued between $32,032 and $480,000. The transaction date is listed as April 10, 2025, with the report published on April 10, 2025.

At present, Abbott Laboratories shares are trading up 1.07% at $125.83.

To stay updated on Josh Gottheimer's trades and other congressional trades, try our government trades tool for live updates!

The Importance of Congressional Transactions

A congressional transaction is when any representative or senator either buys or sells an individual stock.

Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.

In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.

Why Congressional Transactions Matter

Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.

When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.

A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABT Logo
ABTAbbott Laboratories
$133.45-0.42%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
84.44
Growth
99.10
Quality
67.82
Value
44.23
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...